RA Drug May Help Treat Recalcitrant Eczema
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
Treatment with the janus kinase (JAK) inhibitor XELJANZ® (tofacitinib citrate) led to dramatic improvement in six patients with moderate to severe eczema who had previously failed conventional therapies.
As 2025 begins, key trends in aesthetic medicine focus on advancements such as preservation rhinoplasty, personalized body contouring, facial optimization for the digital age, enhanced recovery techniques, and preventative treatments designed to deliver natural results and improve patient outcomes.